Humoral and Cellular Immune Response to a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients Taking Belatacept.
- Mitchell J
Transplantation[Transplantation] 2022 May 01; Vol. 106 (5), pp. e264-e265. Date of Electronic Publication: 2022 Mar 14.
- Publication Date:
- Competing Interests: D.L.S. has received consulting and speaking honoraria from Sanofi, Novartis, CLS Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific, Regeneron, and Astra Zeneca. A.H.K. has received consulting fees from Roche. R.K.A. has study/grant support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, Regeneron, Takeda/Shire, and Vir/GSK and is an Associate Reviewer for Transplantation. M.L.L. is the Social Media Editor for Transplantation. The other authors declare no conflicts of interest.
- Page Start: